Gene Therapy for Skin Depressions
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial investigator to get a clear answer.
Is gene therapy for skin conditions generally safe in humans?
How does the treatment KB301 differ from other treatments for skin depressions?
What data supports the effectiveness of the treatment KB301 for skin depressions?
Research on gene therapy for skin conditions shows promise, as gene delivery systems have been developed to target skin cells effectively and sustain gene expression. This suggests that similar approaches could be beneficial for treatments like KB301, which may involve gene therapy techniques.46101112
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with healthy skin or mild to moderate wrinkles and roughness. Participants must have specific areas of skin suitable for treatment, not be pregnant or nursing, agree to contraception if applicable, and have no recent cosmetic procedures or conditions that could affect results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Subjects receive injectable doses of KB301 or placebo, with assessments of COL3A1 transgene expression and skin improvement
Follow-up
Participants are monitored for safety and effectiveness after treatment, including durability assessments
Extension
Cohort 2 subjects may enroll in an extension phase if they have not reverted to baseline, with additional treatments and monitoring
What Are the Treatments Tested in This Trial?
Interventions
- KB301
Find a Clinic Near You
Who Is Running the Clinical Trial?
Krystal Biotech, Inc.
Lead Sponsor